Anticoagulation after catheter ablation of atrial fibrillation: An unnecessary evil? A systematic review and meta-analysis
Related Experiment Video
Updated: Jan 31, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Riccardo Proietti1, Ahmed AlTurki2, Luigi Di Biase3,4
1Department of Cardiac, Thoracic, and Vascular Sciences, University of Padua, Padua, Italy.
Insights
Discontinuing oral anticoagulation after atrial fibrillation ablation is safe, reducing bleeding risk without increasing cerebrovascular events. This meta-analysis suggests a favorable risk-benefit balance for stopping anticoagulation post-ablation.
Area of Science:
- Cardiology
- Clinical Research
- Evidence Synthesis
Background:
- Current atrial fibrillation (AF) management relies on CHA2DS2-VASc scores for cerebrovascular event (CVE) prediction.
- Guidelines recommend continued oral anticoagulation (OAC) post-AF catheter ablation.
- Uncertainty exists regarding persistent CVE risk after successful ablation.
Purpose of the Study:
- To systematically review and meta-analyze studies comparing CVE and bleeding risk in AF patients on or off OAC after catheter ablation.
- To evaluate the risk-benefit ratio of continuing OAC post-ablation based on risk scores.
Main Methods:
- Systematic literature review of studies up to July 31, 2018.
- Inclusion of studies reporting CVE post-AF ablation comparing on- vs. off-OAC patients.
- Random-effects models used for meta-analysis, stratified by CHADS2 and CHA2DS2-VASc scores.
Main Results:
- 16 studies with 25,177 patients (13,166 off-OAC, 12,011 on-OAC) were analyzed.
- No significant difference in CVE incidence between on-OAC and off-OAC groups post-ablation (RR 0.66; 95% CI 0.38-1.15).
- Off-OAC patients experienced significantly less bleeding (RR 0.17; 95% CI 0.09-0.34). AF recurrence impacted treatment effect (P=0.001).
Conclusions:
- The risk-benefit ratio favors discontinuing OAC after successful AF ablation, even in moderate-high risk patients.
- Further investigation is needed for non-vitamin K antagonist oral anticoagulants.
- Suspension of OAT post-ablation appears safe and beneficial regarding bleeding risk.
Background:
Anticoagulation in patients with atrial fibrillation (AF) is currently based on clinical parameters (CHA2 DS 2 -VASc score) that have been shown to predict cerebrovascular events (CVE). Controversy exists as to whether CVE risk persists unmodified after successful catheter ablation, as observational studies suggest a lower risk of CVE. Current guidelines recommend continued oral anticoagulation (OAC) based on the CHA 2 DS 2 -VASc score risk profile.
Methods:
We conducted a systematic literature review of all studies published up to July 31, 2018, that reported CVE after catheter ablation of AF and compared patients on or off OAC. Random-effects models were used to demonstrate the risk of CVE and major bleeding in on-OAC vs off-OAC patients. This analysis was further stratified by CHADS2 and CHA 2 DS 2 -VASc score.
Results:
We retained 16 studies, 10 prospective cohort and 6 retrospective cohort, that met inclusion criteria, and which enrolled 25 177 patients: 13 166 off-OAC and 12 011 on-OAC. No significant difference in the incidence of CVE emerged between on-OAC and off-OAC patients after AF ablation (risk ratio, 0.66; confidence interval [CI], 0.38, 1.15). Similar results were found after stratification by CHADS2 and CHA 2 DS 2 -VASc score. Off-OAC patients suffered significantly less bleeding than those on OAC (RR, 0.17; CI, 0.09, 0.34). Of note, the percentage of patients with AF recurrence impacts the treatment effect in the two groups ( P = 0.001).
Conclusions:
In this metanalysis, the risk-benefit ratio favored the suspension of OAT after successful AF ablation even in patients at moderate-high risk. Whether the reported results can be extended also to non-vitamin K antagonist oral anticoagulants warrants further investigations.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...

